Search Results

You are looking at 1 - 10 of 51 items for :

  • neuroendocrine neoplasms x
Clear All
Open access

Kosmas Daskalakis, Marina Tsoli, Anna Angelousi, Evanthia Kassi, Krystallenia I Alexandraki, Denise Kolomodi, Gregory Kaltsas and Anna Koumarianou

Introduction Neuroendocrine neoplasms (NENs) represent a heterogeneous group of tumours with variable clinical behaviour and unpredictable prognosis. Their incidence has increased substantially in recent years, partly due to the development of

Open access

Xu Han, Xuefeng Xu, Hongyun Ma, Yuan Ji, Dansong Wang, Tiantao Kuang, Wenchuan Wu, Bin Song, Gang Li, Gang Jin and Wenhui Lou

Introduction Pancreatic neuroendocrine neoplasms (pNENs) are rare and heterogeneous neoplasms of the pancreas, which make up 1–5% of all pancreatic neoplasms ( 1 , 2 ). The incidence and prevalence of pNENs have been increasing significantly

Open access

Linfei Yang, Xiao Yu and Yongchao Yang

Introduction The incidence of pancreatic neuroendocrine neoplasm (pNEN), the most aggressive neuroendocrine malignancy among gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), has increased significantly over the past few decades

Open access

Wentao Zhou, Tiantao Kuang, Xu Han, Wenqi Chen, Xuefeng Xu, Wenhui Lou and Dansong Wang

Introduction Pancreatic neuroendocrine neoplasm (pNEN) is a rare malignancy arising from pancreatic islet cells and accounts for 1–2% of all pancreatic tumors ( 1 ). However, with the popularization of abdominal imaging and the promotion of

Open access

Simon Schimmack, Yongchao Yang, Klaus Felix, Markus Herbst, Yixiong Li, Miriam Schenk, Frank Bergmann, Thilo Hackert and Oliver Strobel

Introduction Pancreatic neuroendocrine neoplasm (pNEN), the most aggressive neuroendocrine malignancy, has an increasing incidence, with 3.2 cases per 1,000,000 inhabitants currently being diagnosed annually in the United States ( 1 , 2 , 3

Open access

Dong Cen, Hui Liu, Zhe Wan, Zhongjie Lin, Yanting Wang, Junjie Xu and Yuelong Liang

Introduction Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors that are derived from diffuse neuroendocrine cells. As a result of improved detection of early-stage disease and possibly stage migration, the incidence and

Open access

Małgorzata Fuksiewicz, Maria Kowalska, Agnieszka Kolasińska-Ćwikła, Jarosław B Ćwikła, Łukasz Sawicki, Katarzyna Roszkowska-Purska, Joanna Drygiel and Beata Kotowicz

Introduction Neuroendocrine neoplasms (NENs) constitute a heterogeneous group of increasingly diagnosed and detected tumours derived from neuroendocrine cells, scattered throughout the human body and forming a diffuse endocrine system

Open access

Giulia Bresciani, Angeliki Ditsiou, Chiara Cilibrasi, Viviana Vella, Federico Rea, Marco Schiavon, Narciso Giorgio Cavallesco, Georgios Giamas, Maria Chiara Zatelli and Teresa Gagliano

Introduction Neuroendocrine neoplasms (NENs) are neoplasms with an estimated annual incidence of 6.9/100,000 people in Europe per year, arising from cells of the diffuse endocrine system (DNES) ( 1 , 2 ). NENs represent a wide group of

Open access

Ashley K Clift, Oskar Kornasiewicz, Panagiotis Drymousis, Omar Faiz, Harpreet S Wasan, James M Kinross, Thomas Cecil and Andrea Frilling

’ phenotype with regards to aggressiveness between appendiceal neuroendocrine neoplasms (ANEN) and adenocarcinoma has been described ( 3 , 4 ), their incidence of 0.05/100,000/year ( 5 ) renders clinical experience limited. A median age at diagnosis of 58

Open access

Filippo Ceccato, Diego Cecchin, Michele Gregianin, Giacomo Ricci, Cristina Campi, Filippo Crimì, Marta Bergamo, Annibale Versari, Carmelo Lacognata, Federico Rea, Mattia Barbot and Carla Scaroni

-pituitary neoplasm (ectopic ACTH secretion, EAS) ( 1 , 2 , 3 , 4 ). Achieving the goals of CS treatment (to normalize cortisol levels, to reverse the clinical symptoms and to remove the secreting neoplasm) is a challenge, especially in EAS ( 5 , 6 ). EAS is